Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a common ED drug help heart valve patients breathe easier?

NCT ID NCT07462260

Disease control Sponsor: Sindh Institute of Cardiovascular Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether sildenafil (the drug in Viagra) can help people with severe lung high blood pressure caused by long-term rheumatic heart valve disease. Researchers will give 100 participants either sildenafil or a placebo three times daily for six weeks. The main goal is to see if the drug improves how far they can walk in six minutes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Sildenafil (a drug that relaxes blood vessels in the lungs)
What this could lead to
If it works, this could offer a short-term treatment to improve exercise ability and heart function in people awaiting heart valve surgery.
What could go wrong
This is a small, 6-week trial, so results may not apply to long-term use. Sildenafil can cause side effects like headache, flushing, or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patient with diagnosed rheumatic valvular heart disease 2. Age between 18-\> 80 years 3. Severe pulmonary hypertension Exclusion Criteria: 1. Patient undergoing corrective surgery within 6 weeks 2. Uncontrolled hypertension (\>170/110mmHg) 3. Hypotension (Blood pressure of \< 90/50mmHg) 4. Heart Failure or Coronary Arterial Diseases with Unstable Angina 5. Hypersensitivity to sildenafil or any component of the formulation of sildenafil 6. Prior episode of non-arteritic anterior ischemic neuropathy 7. Stroke in last 6 months 8. Life-threatening arrhythmias 9. MI in last 6 months 10. Patient takes nitrates as essential drug therapy 11. Patient doesn't have a plan for corrective surgery within 6 weeks

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary hypertension rheumatic heart disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary hypertension Rheumatic valvular heart disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sindh Institute of Cardiovascular Diseases

    RECRUITING

    Hyderābād, Sindh, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.